Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-05-03Clinical Trial Update: POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors
This is a clinical cohort study at University Medical Center Groningen evaluating patients with melanoma and non-small cell lung cancer who …
-
CLINICAL_TRIALS research · 2024-05-03Clinical Trial Update: Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance [Phase 2]
This clinical trial update summarizes a Phase 2 study evaluating precision immuno-oncology approaches in advanced non-small cell lung cancer…
-
CLINICAL_TRIALS trial_result · 2024-05-03Clinical Trial Update: Pembrolizumab-PET Imaging [NA]
This clinical trial update notes the completion of a pembrolizumab-PET imaging study involving melanoma and non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2024-05-02Clinical Trial Update: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer [Phase 3]
A phase 3 trial evaluating Aumolertinib with chemotherapy or as monotherapy compared to Osimertinib in EGFR-mutant non-small cell lung cance…
-
CLINICAL_TRIALS research · 2024-05-01Clinical Trial Update: Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial update for KN046 in patients with advanced non-small cell lung cancer; the study is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-05-01Clinical Trial Update: Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer
This clinical trial explores neoadjuvant chemoimmunotherapy for stage IIIA (N2) and IIIB non-small cell lung cancer and is not yet recruitin…
-
CLINICAL_TRIALS research · 2024-04-30Clinical Trial Update: Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer [Phase 2]
A Phase 2 trial evaluating immunosensitized radiotherapy with Evoximab (AK112) plus chemotherapy as neoadjuvant therapy for stage II-III non…
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations [Phase 2]
Phase 2 study evaluating JMT101 in combination with osimertinib for locally advanced or metastatic non-small cell lung cancer with EGFR comm…
-
CLINICAL_TRIALS research · 2024-04-30Clinical Trial Update: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) [Phase 2]
Phase 2 trial update for tomivosertib in combination with pembrolizumab in PD-L1-positive non-small cell lung cancer (KICKSTART) indicates t…
-
FDA approval · 2024-04-29FDA Approved: TAGRISSO — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA approved a supplemental application for TAGRISSO (osimertinib) submitted by AstraZeneca Pharmaceuticals LP. The approval updates the…
-
CLINICAL_TRIALS research · 2024-04-26Clinical Trial Update: Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment [NA]
The document discusses a clinical trial evaluating Lifei Xiaoji Wan for early-stage non-small cell lung cancer (lung adenocarcinoma) and its…
-
CLINICAL_TRIALS research · 2024-04-26Clinical Trial Update: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure [Phase 3]
Phase 3 trial comparing D-1553 tablet to docetaxel injection in KRAS G12C mutation-positive non-small cell lung cancer after prior therapy; …
-
CLINICAL_TRIALS trial_result · 2024-04-26Clinical Trial Update: Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib [Phase 2]
A Phase 2 trial of Alkotinib capsules in ALK-positive non-small cell lung cancer patients previously treated with Crizotinib has been termin…
-
CLINICAL_TRIALS trial_result · 2024-04-26Clinical Trial Update: Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer [NA]
Clinical trial update reporting pathologic and immunologic responses after ablative radiation in non-small cell lung cancer; results were po…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy [Phase 3]
A Phase 3 trial of denosumab in advanced non-small cell lung cancer showed survival improvement; the study was terminated with results poste…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer [Phase 1, Phase 2]
This clinical trial update reports on the completed Phase 1 and Phase 2 study of AK104 in patients with locally advanced or metastatic non-s…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer [Phase 1, Phase 2]
A two-part Phase 1/2 trial of BIW-8962 as monotherapy in lung cancer has been terminated; the study evaluated Non-Small Cell Lung Cancer, Sm…
-
CLINICAL_TRIALS withdrawal · 2024-04-25Clinical Trial Update: Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy [Phase 2]
The Phase 2 trial investigating low-dose radiotherapy's effect on the tumor immune microenvironment in oligometastatic non-small cell lung c…
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations [Phase 3]
Phase 3 trial evaluating JMT101 with osimertinib versus cisplatin-pemetrexed in locally advanced or metastatic NSCLC with EGFR exon 20ins mu…
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy [Phase 2]
Phase 2 clinical trial evaluating nivolumab after neoadjuvant therapy and concurrent chemoradiation for stage III non-small-cell lung cancer…
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy [Phase 2]
Phase 2 trial evaluating neoadjuvant/adjuvant pembrolizumab combined with chemotherapy for non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2024-04-22Clinical Trial Update: Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases [Phase 2]
Phase 2 trial investigating Almonertinib as first-line treatment for EGFR-mutant advanced non-small cell lung cancer with brain metastases.
-
CLINICAL_TRIALS trial_result · 2024-04-22Clinical Trial Update: Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial investigating Glesatinib, Sitravatinib, or Mocetinostat in combination with Nivolumab for non-small cell lung cancer was termi…
-
CLINICAL_TRIALS trial_result · 2024-04-19Clinical Trial Update: Molecular Disease Characterization Initiative (MDCI) [Phase 2]
Phase 2 trial update for the Molecular Disease Characterization Initiative (MDCI) in non-small cell lung cancer; the study is terminated wit…
-
FDA approval · 2024-04-18FDA Approved: ALECENSA — Supplemental Application (Genentech, Inc.)
FDA approves a supplemental application for Alecensa (alectinib hydrochloride) submitted by Genentech, Inc.